CXCR Inhibitor

4-Amino-D-phenylalanine ([D-Phe(4-NH2)), a cyclic pentapeptide, inhibits CXCL12 binding to CXCR4 in FC131, with an IC₅₀ of 0.1 μM.

CXCR4 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Anti-Mouse CXCR6 Antibody (Cx6Mab-1) is a monoclonal antibody targeting mouse CXC chemokine receptor 6 (mCXCR6), with a K_D of 1.7 nM against CHO/mCXCR6-overexpressing cells. Anti-Mouse CXCR6 Antibody (Cx6Mab-1) binds to the N-terminal domain epitope of mCXCR6 containing Ser8, Ala9, Leu10, Tyr11, Gly13 and His14, and interacts with both overexpressed and endogenous forms of the receptor. Anti-Mouse CXCR6 Antibody (Cx6Mab-1) can be used in studies related to mouse lymphoma.

Cxcr4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Anti-Human/Mouse/Monkey CXCR3 Antibody (9C5) is an antibody targeting CXCR3, which specifically binds to an epitope within amino acid residues 23 to 44 of human CXCR3.

Olaptesed pegol sodium scrambled negative control is the sequence scrambled negative control of Olaptesed pegol sodium.

CXCR2-IN-3 is a CXCR2 inhibitor with an IC₅₀ of 11.37 μM. CXCR2-IN-3 mediates CXCR2-Ca²⁺ signalling inhibition halted autophagic flux, subsequently facilitating ROS-mediated apoptotic cell death. CXCR2-IN-3 suppresses the CXCR2-NLRP3 canonical pathway, suppressing pre-tumorigenic markers. CXCR2-IN-3 causes autophagy-dependent cell death in polyploid giant cancer cells (PGCCs). CXCR2-IN-3 can be used for the research of oral squamous cell carcinoma (OSCC).

Cxcr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Corydalmine hydrochloride inhibits spore germination of some plant pathogenic as well as saprophytic fungi. Corydalmine hydrochloride acts as an oral analgesic agent, exhibiting potent analgesic activity. Corydalmine hydrochloride alleviates Vincristine-induced neuropathic pain in mice by inhibiting an NF-κB-dependent CXCL1/CXCR2 signaling pathway.

TJX7 is a recombinant antibody targeting CXCL13/BCA-1/BLC.

PROTAC STING Degrader-2 is a STING PROTAC degrader with a DC₅₀ of 0.53 μM. PROTAC STING Degrader-2 reduces the phosphorylation levels of TBK1 and IRF3. PROTAC STING Degrader-2 decreases the mRNA expression levels of IFN-β, CXCL10 and TNF-α, and blocks luciferase secretion. PROTAC STING Degrader-2 can be used in the research of autoimmune diseases.

AMD 3329 octahydrobromide is a potent and selective anti-HIV-1 and HIV-2 compound with activity to inhibit viral replication. AMD 3329 blocks viral invasion by binding to the chemokine receptor CXCR4. AMD 3329 exhibits EC₅₀ values as low as 0.8 and 1.6 nM when inhibiting HIV-1 and HIV-2 replication, showing better antiviral efficacy than AMD3100. AMD 3329 significantly inhibits the binding of specific CXCR4 monoclonal antibodies and the Ca(2+) flux induced by SDF-1alpha. AMD 3329 is also able to effectively interfere with virus-induced syncytium formation, with an EC₅₀ value of 12 nM.

Cxcr4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Polyphemusin II-Derived Peptide (T140), a CXCR4 inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4.

PMX464 (AW 464) is a thiol-reactive quinol compound and an inhibitor of the thioredoxin-thioredoxin reductase (Trx/TrxR) system, with an IC₅₀ value of 6.5 μM against TrxR. PMX464 acts by irreversibly inhibiting the thioredoxin (Trx-1) system, blocking HIF-1α transcriptional activation and the NF-κB inflammatory pathway, inducing apoptosis, attenuating platelet function and inhibiting thrombosis, and specifically disrupting the trypanothione antioxidant metabolic network in parasites. PMX464 is used in research concerning malignant tumors (colorectal cancer, breast cancer, renal cancer, and leukemia), pulmonary inflammation, African sleeping sickness, and antithrombotic applications.

cGAS-IN-9 is a cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) inhibitor, with IC₅₀ values of 27.5 nM and 5.15 μM against human and murine cGAS, respectively. cGAS-IN-9 shows weak inhibitory activity against human soluble adenylate cyclase, with an IC₅₀ of 26.4 μM. cGAS-IN-9 inhibits dsDNA-induced expression of IFNB1 and CXCL10, as well as activation of the NF-κB pathway, in human immune cells. cGAS-IN-9 can be used in research related to cGAS-dependent inflammatory diseases.

BC-1485 is a small molecule inhibitor of Fibrosis-inducing E3 ligase 1 (FIEL1). BC-1485 protects PIAS4 from ubiquitin-mediated degradation. BC-1485 decreases α-SMA, BAL and CXCL1. BC-1485 ameliorates fibrotic lung injury in murine models.

Centella asiatica extract is an orally active herbal extract. Centella asiatica extract scavenges free radicals, increases stratum corneum hydration, improves epidermal barrier function, and reduces skin redness and skin pH. Centella asiatica extract inhibits pro-inflammatory cytokines, suppresses p38 MAPK phosphorylation, reduces mast cell infiltration, and decreases the expression of TNF-α, IL-4, IL-5, IL-6, IL-17, CXCL9, iNOS and COX-2. Centella asiatica extract upregulates the expression of BDNF and downregulates the expression of VGLUT1, and exhibits neuroprotective effects under hypoxic conditions. Centella asiatica extract inhibits pro-inflammatory M1 macrophage polarization and prevents adipose tissue senescence. Centella asiatica extract can be used in studies related to hypoxia-induced neurological dysfunction, atopic dermatitis, and obesity-induced insulin resistance.

CXCR4-IN-1 (Example C5) is a CXCR4 inhibitor (IC₅₀: 20 nM). CXCR4-IN-1 can be used for research of cancer, HIV, diabetic retinopathy, inflammation, etc.